<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926584</url>
  </required_header>
  <id_info>
    <org_study_id>KOMPASSneo</org_study_id>
    <nct_id>NCT04926584</nct_id>
  </id_info>
  <brief_title>Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option</brief_title>
  <acronym>KOMPASSneo</acronym>
  <official_title>Prospective Trial of Immunotherapy Prior to Resection, Definitive Chemo-radiotherapy, or Palliative Therapy in Patients With Locally Advanced or Oligometastatic Non-small Cell Lung Cancer Without a Primary Curative Option</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Esslingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum Esslingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a certified lung- cancer center, patients with NSCLC and a potentially curative stage&#xD;
      (including patients with oligometastatic disease) are prospectively enrolled if curative&#xD;
      treatment (either definitive radio-chemotherapy or resection) cannot be performed due to&#xD;
      large tumor size or for functional reasons. For these patients, the multidisciplinary tumor&#xD;
      board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed&#xD;
      radiologically including PET-CT if indicated. After review of the MDB, patients receive&#xD;
      either definitive curative treatment or palliative treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a certified lung- cancer center, patients with NSCLC and a potentially curative stage&#xD;
      (including patients with oligometastatic disease) are prospectively enrolled if curative&#xD;
      treatment (either definitive radio-chemotherapy or resection) cannot be performed due to&#xD;
      large tumor size or for functional reasons (e. g. too large radiation field or functionally&#xD;
      inoperable for the required resection). For these patients, the multidisciplinary tumor board&#xD;
      (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically&#xD;
      including PET-CT if indicated. After review of the MDB, patients receive either definitive&#xD;
      curative treatment or palliative treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>patients completing definitive therapy</measure>
    <time_frame>1 year</time_frame>
    <description>proportion of patients completing definitive therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete or partial radiologic response</measure>
    <time_frame>1 year</time_frame>
    <description>proportion of patients who achieved complete or partial radiologic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local downstaging</measure>
    <time_frame>1 year</time_frame>
    <description>proportion who achieved local downstaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete metabolic response</measure>
    <time_frame>1 year</time_frame>
    <description>proportion who achieved complete metabolic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>event-free survival (EFS)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction therapy</intervention_name>
    <description>induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced or oligometastatic NSCLC (stage IIIA - IVA) wae elegible if&#xD;
        curative treatment (either resection or chemoradiotherapy is not possible for anatomical or&#xD;
        functional reasons&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newly diagnosed NSCLC&#xD;
&#xD;
          -  histologically or cytologically proven&#xD;
&#xD;
          -  stage III - IVA (oligometastatic) by complete staging&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  life expectancy 3 months&#xD;
&#xD;
          -  ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  primary resectability&#xD;
&#xD;
          -  primary definitive chemoradiotherapy feasible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Faehling, MD, MSc</last_name>
    <phone>+49711310382411</phone>
    <email>m.faehling@klinikum-esslingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Landmesser</last_name>
      <email>studienbuero@klinikum-esslingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Esslingen</investigator_affiliation>
    <investigator_full_name>Martin Faehling</investigator_full_name>
    <investigator_title>Head of Pneumology</investigator_title>
  </responsible_party>
  <keyword>immunotherapy, chemoradiotherapy, resection, PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

